dual IGF-1R/IR inhibitors (OSI)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namedual IGF-1R/IR inhibitors (OSI)
Drug Alias Nameinsulin-like growth factor-1 receptor/insulin receptor inhibitors (OSI)FQITOSI-971
ClassificationSmall molecules
Mechanisms of ActionInsulin receptor inhibitorsAnticancer protein kinase inhibitorsInsulin-like growth factor I receptor antagonists
TargetsInsulin receptorInsulin-like growth factor I receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOsi Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstellas Pharma IncOsi Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A